Interlukin-6 Receptor Inhibitor Tocilizumab
نویسندگان
چکیده
منابع مشابه
Association between Interlukin-6 (IL-6), Interlukin-10 (IL-10) and depression in patients undergoing Hematopoietic stem cell transplantation
BACKGROUND The release of pro-inflammatory cytokines is responsible for the variety of behavioral, neuro-endocrine and neuro-chemical alterations in psychiatric condition. In this study we evaluate relation between depression and IL-6 and IL-10 in patients undergoing hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS 66 patients in this cross-sectional study from July 2013 ...
متن کاملTocilizumab, an interleukin-6 inhibitor: a steroid sparing agent in giant cell arteritis.
The Giant Cell Arteritis Actemra (GiACTA) study, the largest randomised trial for this disease to date, involved 251 patients and describes the benefits of tocilizumab, an interleukin-6 inhibitor.1 Patients were randomised to one of 4 groups, in a ratio of 2:1:1:1, to receive: subcutaneous tocilizumab 162 mg weekly (100 patients); or every 2 weeks (50 patients); or placebo (one arm of 50 patien...
متن کاملSystematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
BACKGROUND Tocilizumab (TCZ), a humanized anti-interleukin-6 receptor monoclonal antibody, represents a new treatment strategy for patients with rheumatoid arthritis (RA) and is currently approved in the United States for RA patients who have failed to improve with at least one anti-tumor necrosis factor therapy. OBJECTIVE The goal of this study was to summarize the efficacy and safety profil...
متن کاملTocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Interleukin (IL)-6 has a variety of biological functions. For example, it stimulates the production of acute-phase reactants (C-reactive protein and serum amyloid A) and hepcidin which interferes with iron recycling and absorption, causing iron-deficient anemia, and augments expression of vascular endothelial growth factor and receptor activator of nuclear factor-κB ligand in synovial cells, le...
متن کاملSuccessful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab.
IMPORTANCE A patient with a Caspr2 autoantibodies-associated syndrome had an unusual clinical triad and an excellent response to B-cell-anergizing therapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) receptor. OBSERVATIONS A 55-year-old man had an atypical clinical triad of epilepsy, dysarthria, and paroxysmal kinesigenic dystonia, and a high t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurosurgery
سال: 2008
ISSN: 0148-396X,1524-4040
DOI: 10.1227/01.neu.0000335796.72760.ec